We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
OZEMPIC (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
OZEMPIC
Date registered
Evaluation commenced
Decision date
Approval time
177 working days (255)
Active ingredients
semaglutide (rys)
Registration type
NCE/NBE
Indication
OZEMPIC (solution for injection) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.